Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03193541 · ClinicalTrials.gov registry record
A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer
A clinical trial of Bladder Cancer, sponsored by Cedars-Sinai Medical Center.
- Recruiting
- Registry status
- 900
- Enrollment target
- 8
- Study locations
NCT03193541 is a study of Bladder Cancer that is actively recruiting participants, run by Cedars-Sinai Medical Center. The registered enrollment target is 900 participants, below the 12,749-participant average among 175 other Bladder Cancer trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 5 states.
The verdict
NCT03193541, a study of Bladder Cancer, is actively recruiting participants, sponsored by Cedars-Sinai Medical Center.
- RECRUITING
- Registry status
- 900 participants
- Enrollment target
- 8
- Study locations
Study Summary
To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
Conditions Studied
Study Locations (8)
California
- VA Long Beach Healthcare System - Long Beach
- Cedars-Sinai Medical Center - Los Angeles
- UCLA Medical Center - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
New York
- University of Rochester Medical Center - Rochester
Texas
- UT Southwestern Medical Center at Dallas - Dallas
Nara
- Nara Prefecture Seiwa Medical Center - Nara
Other
- Nara Medical University - Nara
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 900 participants |
| Start Date | 2016-12-30 |
| Est. Completion | 2029-02 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03193541
The ClinicalTrials.gov registry entry for NCT03193541 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 900 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 12,749-participant average among 175 other Bladder Cancer trials with a reported enrollment target (93% lower). The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03193541 reports 8 study locations spanning 5 distinct geographic areas - top geographies include California, New York, Texas.
Frequently Asked Questions
What is clinical trial NCT03193541 about?
NCT03193541 is a clinical study titled "A Novel Multiplex ELISA Assay for Evaluating Patients With Microscopic Hematuria for Bladder Cancer". To improve upon the non-invasive detection of BCa by further validating a multiplex ELISA assay directed at a BCa-associated diagnostic signature in voided urine samples of patients with microscopic hematuria.
What is the current status of trial NCT03193541?
This trial is currently recruiting. The enrollment target is 900 participants. The study started on 2016-12-30. Estimated completion is 2029-02.
What conditions does trial NCT03193541 study?
This clinical trial studies the following conditions: Bladder Cancer.
Who is sponsoring clinical trial NCT03193541?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03193541 being conducted?
This trial has 8 study locations across California, New York, Texas, Nara. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.